GlassScriptPhysician profile
Chris T Geohas
NPI 1659377398
$4,799.45
in general payments reported to CMS, 2019-2025
31 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $236 · 2021: $314 · 2022: $1,226 · 2023: $841 · 2024: $548 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,231.35 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $404.61 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $359.25 | 2019-2025 | |
| Atricure, INC. | $279.02 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $274.70 | 2019-2025 | Lifevest |
| Abiomed | $263.50 | 2023-2025 | Impella |
| Biosense Webster, INC. | $237.12 | 2019-2020 | |
| Pfizer INC. | $191.82 | 2022-2025 | |
| Cleerly, INC. | $180.33 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Medtronic, INC. | $162.52 | 2022-2023 | Endurant Iis |
| Boston Scientific Corporation | $158.95 | 2019-2024 | Watchman Flx, Watchman Access System |
| Abbott Laboratories | $143.04 | 2019-2023 | Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $139.35 | 2023-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $139.20 | 2019-2023 | Xarelto |
| Tactile Systems Technology INC | $114.76 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.96 | 2023-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.79 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $46.33 | 2020-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $43.43 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $39.11 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $30.67 | 2022 | |
| Endotronix, INC. | $24.06 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Cvrx, INC. | $20.16 | 2024 | Barostim Neo System |
| Philips North America LLC | $19.87 | 2024 | (Ck4) Mcot |
| Cook Medical LLC | $18.52 | 2020 | |
| Kestra Medical Technology Services, INC. | $17.37 | 2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $17.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2025 | |
| Amarin Pharma, INC. | $16.59 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Geohas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.